Format

Send to

Choose Destination
Rev Alerg Mex. 2018 Oct-Dec;65(4):357-361. doi: 10.29262/ram.v65i4.367.

[Study on immunotherapy safety: clinical practice in allergy outpatient care].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Hospital Universitario La Paz, Servicio de Alergología, Madrid, España. margui.tomas@gmail.com.

Abstract

in English, Spanish

BACKGROUND:

Immunotherapy with specific allergens is the only immune system-modifying treatment for allergic disease.

OBJECTIVE:

To identify the prevalence of adverse reactions during the subcutaneous immunotherapy initiation phase in real-life conditions and possible associated risk factors.

METHODS:

One-year retrospective, observational study. Epidemiological characteristics of 481 patients, type of immunotherapy used and adverse reactions were recorded.

RESULTS:

16.8% of patients suffered atopic dermatitis, 8.9% food allergy, 4% drug allergy and 7.3 % had experienced idiopathic urticaria. Grass pollen was the main allergen. In polysensitized patients, the use of polymerized extracts that contained grasses in their composition was higher (89.2%) than that of native extracts (78.9%). A total of 1292 doses of specific immunotherapy were administered: 881 polymerized extracts and 411 depot extracts; 30 patients had an adverse reaction (6.2 %): 4.4% of those who received polymerized extract and 14.3 % of those who received a native one (OR = 3.657). In patients who received polymerized extracts, the adverse reaction was local in 82.4%, mild systemic in 11.8% and only in one it was serious systemic; 66.7 % of those who received native extract had local reactions, 25 % mild systemic and only one, serious systemic.

CONCLUSION:

Subcutaneous immunotherapy under real life conditions is not free of risk, but the incidence of severe reactions is very low, especially with polymerized extracts, even when grouped or ultra-rapid testing is used.

KEYWORDS:

Adverse reaction; Immunotherapy; Safety

PMID:
30602205
DOI:
10.29262/ram.v65i4.367

Supplemental Content

Loading ...
Support Center